1. Home
  2. TVTX vs NVCR Comparison

TVTX vs NVCR Comparison

Compare TVTX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVTX
  • NVCR
  • Stock Information
  • Founded
  • TVTX 2008
  • NVCR 2000
  • Country
  • TVTX United States
  • NVCR Switzerland
  • Employees
  • TVTX N/A
  • NVCR N/A
  • Industry
  • TVTX Biotechnology: Pharmaceutical Preparations
  • NVCR Medical/Dental Instruments
  • Sector
  • TVTX Health Care
  • NVCR Health Care
  • Exchange
  • TVTX Nasdaq
  • NVCR Nasdaq
  • Market Cap
  • TVTX 1.5B
  • NVCR 1.4B
  • IPO Year
  • TVTX N/A
  • NVCR 2015
  • Fundamental
  • Price
  • TVTX $17.92
  • NVCR $12.43
  • Analyst Decision
  • TVTX Strong Buy
  • NVCR Buy
  • Analyst Count
  • TVTX 16
  • NVCR 7
  • Target Price
  • TVTX $33.40
  • NVCR $28.79
  • AVG Volume (30 Days)
  • TVTX 1.5M
  • NVCR 1.9M
  • Earning Date
  • TVTX 08-06-2025
  • NVCR 07-24-2025
  • Dividend Yield
  • TVTX N/A
  • NVCR N/A
  • EPS Growth
  • TVTX N/A
  • NVCR N/A
  • EPS
  • TVTX N/A
  • NVCR N/A
  • Revenue
  • TVTX $333,865,000.00
  • NVCR $630,160,000.00
  • Revenue This Year
  • TVTX $71.61
  • NVCR $6.68
  • Revenue Next Year
  • TVTX $43.45
  • NVCR $7.01
  • P/E Ratio
  • TVTX N/A
  • NVCR N/A
  • Revenue Growth
  • TVTX 87.94
  • NVCR 14.58
  • 52 Week Low
  • TVTX $8.46
  • NVCR $10.87
  • 52 Week High
  • TVTX $25.29
  • NVCR $34.13
  • Technical
  • Relative Strength Index (RSI)
  • TVTX 59.60
  • NVCR 46.30
  • Support Level
  • TVTX $17.24
  • NVCR $11.55
  • Resistance Level
  • TVTX $19.08
  • NVCR $12.26
  • Average True Range (ATR)
  • TVTX 0.87
  • NVCR 0.46
  • MACD
  • TVTX 0.04
  • NVCR 0.30
  • Stochastic Oscillator
  • TVTX 66.67
  • NVCR 97.50

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Share on Social Networks: